Phase 2 study of KHK7580

A randomized, double-blind, parallel-group, dose-finding study of KHK7580 for secondary

Status

Unknown

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2080222580

Enrollment

150

Registered

2014-08-11

Start date

2014-08-11

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Secondary hyperparathyroidism patients receiving hemodialysis

Interventions

investigational material(s) Generic name etc : KHK7580 INN of investigational material : Therapeutic category code : 399 Agents affecting metabolism, n.e.c. Dosage and Administration for Investigatio

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: - Subjects who have voluntarily consented to participate in this study - Subjects with stable chronic renal disease receiving hemodialysis 3 times weekly for at least 12 weeks before screening - Subjects with an intact PTH of >= 240 pg/mL at screening

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Efficacy intact PTH	—

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026